Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy and safety of Icotinib as neoadjuvant in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery.
详细描述
Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy; then patients with clinical benefits receive surgical resection of the tumor. If there is curative effect of Icotinib according to the RECIST or pathological report, the patients will continue receive Icotinib for two years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity. The primary objective of this study is evaluate the efficacy and safety of Icotinib neoadjuvant therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histology or cytology confirmed Non-small Cell Lung Cancer; EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or plasma ctDNA
- •No previous anti-tumor treatment such as surgery, chemotherapy, radiotherapy or biological therapy
- •Stage IIIA N2 NSCLC according to the pathological evidence of endobronchial ultrasound(EBUS) or PET-CT, the short-axis diameter of lymph node 1-2cm, and considered surgically resectable at baseline by the surgical oncologist
- •Sufficient tumor histological specimens (non-cytology) for molecular marker analysis
- •At least one lesion with measurable diameter and its longest diameter is large than 10 mm by CT measurement
排除标准
- •Previous systemic anti-tumor treatment of Non-small Cell Lung Cancer, including cytotoxic drug therapy, targeted drug therapy (tyrosine kinase inhibitors or monoclonal antibodies) and experimental treatment, etc
- •Previous local radiotherapy of Non-small Cell Lung Cancer
- •Be allergic to any component of Icotinib tablet (Conmana)
- •Other cancers within five years prior to the treatment of this study. Except for cervical carcinoma, basal cell carcinoma and bladder epithelial neoplasm (including Ta and Tis)
- •Any instable systemic disease, including: active infection, high blood pressure out of control, unstable angina, onset of angina pectoris within the past 3 months, congestive heart failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic disease
- •Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy or any active intersexual lung disease with clinical evidence
- •Idiopathic pulmonary fibrosis detected by CT scan at baseline;
- •Not fully controlled eye inflammation or infections, or any condition that may lead to the above eye diseases
- •Human immunodeficiency virus infection
- •Patients undergoing major surgery or severe trauma within 2 months prior to the first use of the experimental drug
- •Patients with Small Cell Lung Cancer
- •Pregnant or lactating women
- •Neurological or psychiatric disorders history, including epilepsy or dementia
- •Other situations not appropriate to enter the group considering by the investigators
研究组 & 干预措施
Icotinib
Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
干预措施: Icotinib (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: eight weeks
次要结局
- Time to Tumor Progression(five years after surgery)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(five years after surgery)
- R0 resection rate(eight weeks)
- Disease Control Rate(eight weeks)
- Decrease in cT-stage(eight weeks)
- pathologic complete remission rate(eight weeks)
- Overall survival(five years after surgery)